Phil Low News Today

West Lafayette IN (SPX) Jun 27, 2023 - Adranos Inc., a Purdue-originated company that grew from a doctoral project into an impactful company, has been acquired by a major Costa Mesa, California-based defense products company, Anduril Ind

Low says the gift is enough to fund what would normally amount to 40 years of grant funding for cancer research. However, he adds the funding likely will not last

Cytalux (pafolacianince), a drug that binds to ovarian cancer tissue and glows when exposed to fluorescent light, has been approved by the U.S. Food and Drug Administration (FDA) to help surgeons detect ovarian tumors during surgical procedures in patients.

 E-Mail IMAGE: The image shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site.... view more  Credit: Novosteo Inc. Novosteo Inc., a preclinical-stage biotechnology startup focused on the development of bone-targeted therapeutics, announced Thursday (February 4) the closing of a $5.5 million in Series A financing to advance its development of the first-ever ta...

Date Time Share Bone treatment startup raises $5.5 M in Series A financing, names pharmaceutical leader William Boyle as CEO The image above shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site. The “targeted” bone received Novosteo’s injectable-targeted drug, whereas the control bone did not receive drug, representing current therapies. Comparing the two bones...